In experimental models, TXM peptides have demonstrated protective efficacy mitigating redox-associated cognitive disorders (e.g., mild traumatic brain injury, rotenone-induced toxicity), lowering cytokine levels and NF-kB, attenuating allergic airway disease, restoring catecholamine and insulin release, and improving systolic cardiac function, among others. The gene discussed is NFKB1; the disease is Cognitive impairment.